Galcanezumab treatment in people with migraine and comorbid anxiety and/or depression


  • Galcanezumab treatment reduced the frequency of migraine headache days (MHD) in people with a history of anxiety and/or depression with either episodic migraine (120 mg or 240 mg galcanezumab) or chronic migraine (240 mg galcanezumab).

Why this matters

    As anxiety and depression are common comorbidities in those with migraine, it is essential to characterize the efficacy of migraine medications in this population.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.